CONNECTICUT ONCOLOGY ASSOCIATION MEETING
Meeting Date: Tues. April. 23, 2024 Time: Evening Meeting 6 pm to 8:30 pm
Location: Sheraton Hartford South (formerly Rocky Hill Marriott) Rocky Hill
6 pm registration, 6:20 buffet dinner, 6:40 meeting starts
Topic “Advances in the management in lower risk MDS”. Dr. Amer Zeidan will preview updates in classification of MDS, risk stratification and management updates especially recent positive phase 3 trials.
Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Leukemias and Myeloid Malignancies Program and the Clinical Research team at Yale Comprehensive Cancer Center (YCC). He is also currently serving as the interim chief for the Division of Hematologic Malignancies at YCC. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General Hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, especially myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with a focus on targeted therapies and immunotherapy-based approaches.
Dr. Zeidan has and continues to serve as the principal investigator of multiple investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and the chair of the YCC Protocol Review Committee (PRC). Dr Zeidan also chairs or serves on the steering committees as well as independent data and safety monitoring committees of multiple large clinical trials in myeloid malignancies. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.
Dr. Zeidan has received several prestigious awards including a five-year Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 330 peer-reviewed publications and book chapters. This is a not to be missed program for physicians and staff in every group in CT (hospital based or private.).
Bring your physician colleagues and staff. You may register on the CT Oncology Association website, www.ctoncology.com, or by email to dawnho@aol.com.
We will also be discussing plans for the Connecticut Oncology Association projects and meetings in 2024, and look forward to participation from practice physicians, administration and nurses. All are encouraged to attend. We also extend a warm welcome to any Residents or Fellows who wish to join us.
Please join the Connecticut Oncology Association in thanking our current 2024 Charter Oak Partners to Date for helping us to bring this education program to our members: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech, Merck, Sanofi Genzyme, Seattle Genetics, Taiho Oncology, and Takeda.
We would also like to thank our other 2024 Nutmeg level corporate partners: Abbvie, Astellas, Eisai, Johnson & Johnson, Incyte, Novartis, Pfizer, and PharmaEssentia.
We look forward to welcoming these partners and others in 2024. 2024 Corporate Partner Invitations/Information is available on our web site, www.ctoncology.com .
Please Complete & email the Registration Information Below by Friday, April 15. at noon.
I will be attending the CtOA meeting at 6 pm Yes____ No___
Please register at www.ctoncology.com, Or email to dawnho@aol.com
It is important to provide contact phone and email information, in case of adverse weather or unexpected issues.
Name: ____________ Affiliation:______________________________
Contact Phone #:_______________ Contact Email: ________________________ ______
Staff and Physicians for Connecticut Practices, Physicians and staff No Charge
Corporate Affiliate Members no charge for this webinar, but may be subject to capacity limits
